이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Oculis Holding 관리

관리 기준 확인 0/4

Oculis Holding's CEO는 Riad Sherif, Dec2017 에 임명되었습니다 의 임기는 6.5 년입니다. 는 $ 10.32M 가치에 해당하는 회사 주식의 2.1% 직접 소유합니다. 10.32M. 경영진과 이사회의 평균 재임 기간은 각각 1.6 년과 1.6 년입니다.

주요 정보

Riad Sherif

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	6.8yrs
CEO 소유권	2.1%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

CEO

Riad Sherif (56 yo)

6.8yrs

테뉴어

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

리더십 팀

이름	위치	테뉴어	보상	소유권
Riad Sherif	CEO & Director	6.8yrs	데이터 없음	2.1% CHF 10.8m
Sylvia Cheung	Chief Financial Officer	4yrs	데이터 없음	0.16% CHF 822.5k
Ramin Tadayoni	Chief Scientific Officer	less than a year	데이터 없음	데이터 없음
Virginia Dean	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음
Bastian Dehmel	Chief Development Officer	2.7yrs	데이터 없음	데이터 없음
Páll Jóhannesson	Chief Business Officer	4yrs	데이터 없음	0.60% CHF 3.1m
Rebecca Weil	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음
Snehal Shah	President of Research & Development	less than a year	데이터 없음	데이터 없음
Sharon Klier	Chief Development Officer	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: OCS 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Riad Sherif	CEO & Director	6.8yrs	데이터 없음	2.1% CHF 10.8m
Eric Donnenfeld	Chair of Cornea Scientific Advisory Board	no data	데이터 없음	데이터 없음
Anthony Rosenberg	Independent Chairman	6.4yrs	데이터 없음	0.23% CHF 1.2m
Christophe Baudouin	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Peter Kaiser	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Lionel Carnot	Independent Director	6.8yrs	데이터 없음	데이터 없음
Christina Ackermann	Independent Director	1.5yrs	데이터 없음	0.028% CHF 144.3k
Quan Dong Nguyen	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Robert Warner	Director	less than a year	데이터 없음	데이터 없음
Arshad Khanani	Chair of Retina Scientific Advisory Board & Director	1.8yrs	데이터 없음	데이터 없음
Anat Loewenstein	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Pablo Villoslada	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: OCS 의 이사회는 경험(평균 재직 기간 1.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Oculis Holding 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG Announces Board and Committee Appointments

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

High number of new and inexperienced directors

Recent updates

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024

Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Holding AG Announces Board and Committee Appointments

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new and inexperienced directors

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령